The FDA has issued a warning that GLP-1 drugs, used for obesity and diabetes, may increase the risk of a rare but serious eye condition sometimes called an “eye stroke,” according to STAT.
This warning raises regulatory and safety concerns for pharmaceutical companies involved in the development and marketing of GLP-1 drugs. Leaders in the sector may need to assess current safety data and consider adjustments to product labelling, as well as prepare for possible changes in prescribing practices.
